Caplyta: Uses, Dosage, Side Effects & Warnings - Drugs.com
Dec 15, 2025 · Caplyta is used to treat adults with schizophrenia, depression associated with bipolar I or bipolar II disorder (manic depression), or along with antidepressant medicines to treat major …
Patient Information | CAPLYTA® (lumateperone)
Explore how CAPLYTA may help with depressive episodes in adults with MDD and bipolar I & II depression. See if you're eligible to save. Please see Medication Guide, including Boxed WARNINGS.
Caplyta: A New Add-On Option for Adults With Depression - WebMD
Nov 6, 2025 · Caplyta (lumateperone), a once-daily oral medicine, has been approved to be used with antidepressants to treat major depressive disorder (MDD) in adults.
FDA approval of CAPLYTA® (lumateperone) has the potential to reset ...
Nov 6, 2025 · FDA approval of CAPLYTA ® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder CAPLYTA®, in …
Lumateperone (Caplyta) | National Alliance on Mental Illness (NAMI)
Lumateperone is also FDA approved for the treatment of depressive episodes of bipolar disorder and as an adjunctive treatment of major depressive disorder (this means lumateperone is used in addition to …
Caplyta: Side effects, use for bipolar, cost, dosage, and more
Nov 13, 2025 · Caplyta is a brand-name medication used to treat schizophrenia, bipolar disorder, and depression in adults by affecting neurotransmitters in the brain. More common side effects of Caplyta …
LUMATEPERONE (Caplyta) Fact Sheet Bottom Line: Lumateperone is the newest second-generation antipsychotic, approved to treat adults with schizophrenia or bipolar disorder. It appears to have a …
CAPLYTA® (lumateperone) | For Healthcare Professionals
CAPLYTA is an FDA-approved treatment option in adults with schizophrenia, bipolar I and II depression, and as an adjunctive therapy for major depressive disorder (MDD). Please see full Prescribing …
New Phase 3 Study Results on Lumateperone, An ... - Psychiatric Times
Apr 16, 2024 · Positive topline results from study 501 showed that lumateperone (Caplyta) 42 mg was effective as an adjunctive therapy to antidepressants for the treatment of major depressive disorder …
Caplyta From Johnson & Johnson - Pharmacy Times
2 days ago · The FDA recently approved lumateperone (Caplyta; Johnson & Johnson) as an adjunct therapy with antidepressants for the treatment of adults with major depressive disorder (MDD). 1 …